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BACKGROUND: This study aimed to identify predictors of response to anthracycline-based chemotherapy (5-fluoro-uracil, epirubicin,
cyclophosphamide (FEC)) in locally advanced primary breast cancer (LAPC).
METHODS: A total of 91 LAPC patients were treated with six cycles of FEC before surgery. Protein expression of nine biomarkers
(topoisomerase2a (Topo2a), ER, PR, HER2, Ki67, p53, EGFR, CK5/6 and CK14) was assessed in pre-chemotherapy core biopsies
using immunohistochemistry (IHC) and results correlated with clinical and pathological response.
RESULTS: Clinical (cCR) and pathological (pCR) complete response were seen in 34.1% (n¼31) and 20% (n¼18), respectively.
Pathological complete response was concordant with cCR in 14/31 cases; in four cases of cPR with palpable residual breast tumours,
histology showed fibrous tissue only (pCR). On univariate analysis, pre-chemotherapy high expression of Topo2a protein (P¼0.031),
and negativity for ER and EGFR (P¼0.001 and P¼0.005, respectively) correlated with pCR. Positivity for p53 also showed
significance (P¼0.015), whereas basal phenotype, HER2, and all the clinicopathological variables of LAPC included in this study did
not show significant correlation with response. On multivariate analysis, Topo2a expression had the strongest correlation with pCR
(P¼0.021) followed by EGFR (P¼0.044).
CONCLUSION: The study suggests that pre-chemotherapy Topo2a protein expression measured by IHC strongly correlates with
pathological CR to neo-adjuvant anthracyclines in this group of LAPC studied.
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Neo-adjuvant chemotherapy is an established treatment modality
for locally advanced primary breast cancer (LAPC) (Mieog et al,
2007). It aims to reduce the size of the primary tumour, to enable
complete surgical removal of the primary tumour and axillary
lymph-node metastases, and in smaller/earlier tumours it may
allow breast conservation and other oncoplastic options without
compromising tumour control. In addition, serial biopsies taken
during neo-adjuvant chemotherapy offers the chance of indivi-
dualization of therapy by offering the scope of evaluating early
molecular changes of various biological or pathological markers
predictive of response or resistance.
The optimal neo-adjuvant combination for the individual
patient is a worthy research question. Anthracycline-based regi-
mens are commonly used because it is one of the most effective in
this setting. The reported clinical (cCR) and pathological (pCR)
complete response rates for anthracycline alone and anthracycline
combination regimes are in the range of 30–40% and 13–26%,
respectively (Mieog et al, 2007). Furthermore, there are about 5%
of breast cancers, which are resistant (have clinically progressive
disease) to neo-adjuvant anthracycline chemotherapy. In these
cases, unnecessary side effects such as cardio-toxicity may be
avoided if biomarkers of response are identified.
Integral to the action of anthracyclines is the inhibition of
topoisomerase2a (Topo2a). This subclass of topoisomerase binds
DNA and forms transient double-stranded breaks in replicating
DNA, allowing passage of a second DNA double-helix strand.
Inhibition of Topo2a leads to double-strand DNA breaks and
cell death (reviewed by Di Leo et al, 2008). Previous studies have
demonstrated that Topo2a is a predictor of response to
anthracycline-based therapy (MacGrogan et al, 2003; Durbecq
et al, 2004). However, other studies have indicated that other
markers such as HER2 (Sa ´nchez-Mun ˜oz et al, 2008) or basal
phenotype (BP) (Rakha et al, 2008) may provide predictor
information. Proliferation as assessed by Ki67 has also been
shown to correlate with outcome (Bozzetti et al, 2006). Therefore,
in this study we assessed the predictive value of multiple molecular
biomarkers in a series of 91 patients presenting with LAPC who
had been offered anthracycline-based therapy.
MATERIALS AND METHODS
Patient treatment profile
A total of 91 patients presenting with LAPC between December
1996 and December 2009 at our institution and treated with
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this study. A core biopsy was performed before the chemotherapy
treatment to allow a pathological diagnosis and evaluation of
biological parameters. Patients were treated with the following
regimen.
Six cycles of an anthracycline-based therapy (FEC: 5-fluoro-
uracil (5-FU) 500mgm
 2, epirubicin 75–100mgm
 2, cyclophos-
phamide 500mgm
 2, on day 1 of a 21-day cycle). Patients were
scheduled to undergo surgery 4 weeks after the sixth cycle.
Assessment of response
Assessment of the tumour response was undertaken by clinical
measurements both before chemotherapy treatment and after each
cycle of chemotherapy. The clinical baseline and preoperative
measurements were obtained with a calliper by the same clinician
or by radiological assessment. Clinical response was recorded
according to RECIST criteria (Park et al, 2003a).
The pathological response was evaluated by histological
examination of tumour removed following chemotherapy. The
surgical procedures that were performed included the following:
Simple mastectomy (13.7%), Patey mastectomy (82.9%) and wide
local excision (3.4%). Histology including grade was reviewed and
agreed upon by two experienced breast pathologists utilising the
Chevallier classification: the absence of invasive tumour cells or
persistence of only in situ disease, and negative axillary lymph
nodes define a pathological CR (Chevallier et al, 1993). On
an average, 16 breast blocks and all submitted lymph nodes
(in entirety) were examined for each case before a diagnosis of
pCR was reached.
Immunohistochemistry techniques for biomarkers
Immunohistochemistry was done on core biopsies (pre-treatment)
with the use of a standard avidin–biotin peroxidase technique
(Madjd et al, 2003). Heat-induced epitope retrieval consisting
of 20-min microwave treatment (10min at high power and 10min
at low power) in pH 6.0 citrate buffer was necessary for all
markers, except HER2. For Ki67 staining, sections were treated
with 10% trypsin before heat-induced antigen retrieval. Sources
and dilution of primary antibodies are summarised in Table 1.
Evaluation of staining
Two observers, blinded to the clinicopathological data, evaluated
the staining for consensus. Cut-off values for scoring are
summarised in Table 1. The cut-off values were chosen as
per standards peer-reviewed and well accepted in literature
(Rakha et al, 2006, 2007). For Topo2a, the median was chosen as
the cut-off for high and low staining as the data distribution is not
homogeneous (Supplementary Figure 1).
Statistical analysis
Statistical analysis was performed using SPSS17 statistical software
(SPSS Inc., Chicago, IL, USA). Pearson’s w
2-tests were used to
determine the significance of associations between categorical
variables. Overall survival (OS) calculations included all patients
who died during follow-up. Survival rates were calculated using the
Kaplan–Meier method; differences between groups were tested
using the log-rank test. Events for relapse-free and OS were defined
as follows: time of disease relapse, either local or distant
(for relapse-free survival), and time of death, (for OS), respectively.
The Cox proportional-hazards model was used for multivariate
analysis in order to determine the relative risk and independent
significance of individual factors. In all cases two-sided P-values of
o0.05 were considered as statistically significant.
RESULTS
Clinicopathological characteristics
The mean age of the patients was 51 years (range 25–76 years).
Histologically, the tumours were classified as follows: Ductal NST
83 (91.2%); lobular (8.8%). The tumours were T’s taged as follows:
T2 14 (15.6%); T3 72 (79.2%); T4 5 (5.2%). Four of these were
inflammatory breast cancers. The grades of the tumours were as
follows: G1 1 (1%); G2 40 (44%); G3: 50 (55%). The N-stage
for such cases treated by neo-adjuvant therapy may not be very
accurate as it is based on clinical examination and not all palpable
lymph nodes may be involved by tumour. Hence this was not
included in the paper. By definition, the M status of locally
advanced breast cancer patients is M0 and this was confirmed in
the current series.
The characteristics of the tumours analysed by IHC are
summarised in Table 2.
Response to chemotherapy regimens
The overall response to anthracycline combination was as follows:
cCR 31 (34.1%); cPR 42 (46.2%) (cORR 80.3%); cSD 15 (16.4%);
cPD 3 (3.3%). Pathological complete response was observed in
18 patients (20%). Clinical CR conformed to pCR in 14 cases; in
4 cases of clinical partial response, histology showed fibrous tissue
only (pCR).
Table 1 Source, dilution and cut-off values for positivity for different biomarkers
Marker
Antibody
(Source)
Optimal
dilution
Positive-control
tissue Cut-off values for positivity
ck5/6 D5/16 B4 (Dako UK Ltd, Ely,
Cambridgeshire, UK)
1:100 Tonsil 10%
ck14 LL002 (Vector Labs,
Peterborough, UK)
1:100 Skin 10%
ER 1D5 (Dako UK Ltd) 1:100 Breast 1%
PGR PGR 636 (Dako UK Ltd) Neat Breast 1%
HER2 DakoA0485 (Dako UK Ltd) 1:500 Breast 30% membranous (corresponds to IHC 3+), or if IHC 2+, confirmed by FISH+
p53 DO7 (Dako UK Ltd) 1:100 Breast 10% nuclear
EGFR EGFR.113 (Dako UK Ltd) 1:50 Skin 10% membranous
Topo2a KI-S1 (Dako UK Ltd) 1:100 Tonsil 45% nuclear (high)
KI67 MIB1 (Dako UK Ltd) 1:100 Tonsil 10% nuclear (high)
Positive-control tissue is also indicated. Positive HER2 was defined as presence of membrane expression of the protein in 430% of tumour cells (corresponds to IHC 3+) or if
underexpressed (2+), confirmed by FISH (fluorescent in situ hybridisation). For p53, Topo2a and Ki67, 100 nuclei were scored for positivity in four random fields ( 40
magnification) and the total percent-score obtained. Median values of Topo2a were chosen as cut-offs for high or low expression. Other standard cut-offs as per Rakha et al
(2006, 2007).
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Immunohistochemistry results. The relationship of immunohis-
tochemical markers and pCR are summarised in Table 2 (and
Supplementary Table2). On univariate analysis, the following
biomarkers correlated with pCR to anthracyclines: Pre-chemo-
therapy high Topo2a expression (P¼0.031), ER– (P¼0.001),
EGFR  (P¼0.005) and p53þ (P¼0.015). Patient age (P¼0.65),
tumour size (P¼0.7), histological subtype (P¼0.58), tumour
grade (P¼0.112), HER2 status (P¼0.354), progesterone receptor
status (P¼0.116) and Ki67 (P¼0.71) did not predict response to
anthracycline-based therapy. There was no correlation between
Topo2a protein expression and HER2 protein expression in the
examined series (P¼0.692). Neither was there any correlation
between Topo2a and Ki67 (P¼0.9) in this study.
For this study, the BP was defined as immuno-phenotypic
evidence of basal cytokeratins CK5/6 and/or CK14 expression
(410%) (Rakha et al, 2006). The BP was highly expressed in
48 patients (52.7%). The BP status was not significant for response
to neo-adjuvant chemotherapy (P¼0.26). When defined as BP and
EGFRþ, the incidence of the BP is 23.9%; this was also not
significant for response to neo-adjuvant chemotherapy (P¼0.5)
(Nielsen et al, 2004). In all, 44% of the BPþ cases are p53 positive.
This is however not statistically significant. The incidence of
triple-negative cancers in the series is 24.1%.
Multivariate analysis was conducted including ER status, EGFR
status, p53 and Topo2a protein status as variables in the regression
equation. Topo2a protein expression correlated with pCR
(P¼0.021; estimated HR: 6.587; 95% confidence intervals
(CI): 1.327–32.707; of the other variables, EGFR– status was also
significant (P¼0.044; estimated HR; 4.765; 95% CI: 1.045–21.729).
Both ER (P¼0.64) and p53 (P¼0.422) failed to achieve
significance.
Survival analysis
Pathological complete response for the series correlated with better
relapse-free (P¼0.005) and OS (P¼0.006) (Figure 1A and B).
A total of 31 patients included in this study had relapsed after their
neo-adjuvant chemotherapy; the median follow-up was 62 months.
A total of 21 patients have died from breast cancer during the
period. The estimated mean RFS for those who achieved pCR was
140 months. For those who had progressive disease, the estimated
median OS was 7 months.
Table 2 Immunohistochemistry analysis and correlations with pCR for patients treated with anthracyclines
Parameter Variables % %pCR %non-pCR P-values Odds ratio
ER status Positive 51.6 6.4 93.6 0.001 0.132 (0.35–0.496)
Negative 48.4 34.1 65.9
PR status Positive 36.3 12.1 87.9 0.116 2.636 (0.765–9.080)
Negative 49.4 26.7 73.3
Missing 14.3 NA NA
HER2 Status Positive 29.7 14.8 85.2 0.354 0.562 (0.164–1.923)
Negative 60.4 23.6 76.4
Missing 9.9 NA NA
Topo2a status High 51.6 28.9 71.1 0.031 3.331 (1.076–10.315)
Low 48.4 13.9 86.1
EGFR status High 63.5 12.5 87.5 0.005 0.186 (0.053–0.647)
Low 36.5 43.5 56.5
p53 status High 39.7 36 64 0.015 4.781 (1.278–17.884)
Low 60.3 10.5 89.5
Ki67 status High 45.3 25 75 0.71 1.286 (0.390–4.238)
Low 54.7 20.6 79.4
Basal phenotype status Positive 52.7 14.9 85.1 0.26 0.542 (0.185-1.587)
Negative 47.3 24.4 75.6
Abbreviation: not applicable. The columns for % pCR and % non-pCR show the response in each category of immunohistochemical variable (positive/negative; high/low). The
Pearson’s w
2-significance is presented in the P-value column. The Odds ratios with 95% confidence intervals are shown in brackets.
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Figure 1 Overall survival (A) and relapse-free survival (B) analysis for
patients with pCR and non-pCR to anthracyclines.
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high, respectively. However, Topo2a status did not predict either
relapse-free (P¼0.67) or OS (P¼0.76) (Figure 2A and B).
Similarly, although patients with BP tumours tend to have a worse
OS and RFS, this was not statistically significant (P¼0.5 and
P¼0.54, respectively) (Figure 3A and B).
DISCUSSION
Neo-adjuvant chemotherapy for patients with LAPC has been
shown to increase surgical resectability and breast conservation
rates (Mieog et al, 2007). A unique advantage of primary
chemotherapy is the possibility to take serial measurements
and biopsies of the primary tumour, thus allowing an in vivo
assessment of factors predictive of response or resistance to
treatment.
The use of anthracycline regimen in the adjuvant setting has
reduced mortality due to breast cancer (Cardoso and Piccart,
2003), but significant cardiac toxicity leading to congestive cardiac
failure has been reported in 3.7% of patients treated with
doxorubicin (Chan et al, 1999). It is clear that the use of the drug
should be avoided in resistant tumours. Hence, the search for
biomarkers predictive of resistance to neo-adjuvant anthracycline
containing regimes is important.
Pathological complete response is the most reliable end-point of
response to neo-adjuvant treatment and hence was chosen in this
study. Pathological complete response for the series correlated
with better OS. Factors associated with pCR on univariate analysis
include Topo2a, EGFR, ER and p53.
The evidence in literature for and against Topo2a as a marker
for response to anthracyclines is variable. The main role of Topo2a
has been explored as a prognostic and predictive biomarker for
anthracyclines in the adjuvant setting and the results thus have
been far contradictory. This study is unique in that it deals with a
pure cohort of patients of locally advanced breast cancer who did
not have any treatment (surgery, radiotherapy, chemotherapy or
hormonal therapy) before anthracycline chemotherapy.
This study evaluated Topo2a protein expression as adjudged by
IHC. Previous studies looking at anthracyclines and Topo2a have
utilised different end-points viz. gene expression or protein
analysis. Topo2a is regulated at multiple levels, viz. at the gene
level (amplification and deletion), post-translational mechanisms
such as mRNA stabilisation, subcellular protein distribution and
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Figure 2 Overall survival (A) and relapse-free survival (B) analysis for
patients with low and high Topo2a protein levels.
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Figure 3 Overall survival (A) and relapse-free survival (B) analysis for
patients either positive or negative for basal phenotype (BP).
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though criticised as being semi-quantitative is a holistic end-point.
Protein expression summates the net-effects of gene translational
and proliferation controls, and hence was chosen for this study.
Only nuclear staining was considered positive, taking into account
the active subcellular location. Tumour-proliferation status is
known to have a key role in regulating Topo2a protein levels,
independently of Topo2a gene status (Di Leo et al, 2008). In our
series, however, no correlation was observed between Topo2a and
Ki-67 protein levels and differential chemosensitivity does not
appear to be simply a function of the proliferation status of the
tumour. It is important to stress here that the LAPC cohort
represents a highly selected population with most tumours being
either grade 2/3 (98%) and having a high proliferation index
(79% with Ki67 410%).
Our results showed that Topo2a protein as measured by IHC in
pre-chemotherapy tumours strongly correlates with pCR. This
concords with the results reported previously (MacGrogan et al,
2003; Martin-Richard et al, 2004) that show that the response to
neo-adjuvant chemotherapy was correlated with the IHC expres-
sion of Topo2a. Recent reports in the adjuvant setting also confirm
that Topo2a protein rather than gene expression correlates with
response to anthracycline-based therapy (Schindlbeck et al, 2010).
Park et al (2003b) reported a good response to doxorubicin in
breast cancers with co-amplification of HER2 and Topo2a
(as measured by chromogenic in situ hybridisation) and in
HER2-amplified tumours with or without Topo2a amplification.
Co-amplification of HER2 and Topo2a also correlated with
response to anthracycline-based therapy in a series of high-risk
primary breast cancers (Konecny et al, 2010). In our studies, there
was no correlation between HER2 and Topo2a expression as
measured by IHC, and HER2/Topo2a co-expression on a protein
level did not correlate for response to anthracyclines. Recent
reports from the MA.5 trial show that Topo2a protein over-
expression is not closely correlated to HER2 positivity but is a
significant predictor of differential response to anthracycline
combination chemotherapy (O’Malley et al, 2006). This study did
not preselect for HER2-positive patients treated with anthracy-
clines. We concur with the view that the ‘jury is still out’ over this
issue with both proponents and opponents for such selection
(Esteva and Hortobagyi, 2009).
The predictive value of Topo2a protein levels in the neo-
adjuvant setting in locally advanced breast cancer parallels other
retrospective studies in early or advanced breast cancer. In the
adjuvant setting, a dose-intense anthracycline-based chemo-
therapy showed superiority over a less intensive regimen only in
the cohort of patients carrying Topo2a protein overexpression
(Di Leo et al, 2001). Results from a retrospective phase III clinical
trial conducted by the National Cancer Institute – Canada Group
also confirm that Topo2a protein overexpression might be
associated with increased benefit from doxorubicin (hazard ratio
1.09, 95% CI: 1.03–1.15, P¼0.002) (Durbecq et al, 2004).
The prospective TOP trial that was specifically designed to
identify markers of response/resistance to preoperative epirubicin
in oestrogen receptor-negative breast cancer patients, showed that
Topo2a amplification (as identified by FISH) was exclusively
observed in HER2-amplified cases and was highly predictive of
pCR (Desmedt et al, 2009). In contrast to this study, protein levels
were not predictive of pCR. In another small series of 23 patients
with endocrine unresponsive and HER2-overexpressing tumours,
Topo2a amplification correlated with a significantly high prob-
ability of achieving pCR after neo-adjuvant, anthracycline-based
chemotherapy (Orlando et al, 2008).
In spite of being correlated with pCR, Topo2a protein levels did
not show any particular trend in the cases that had progressive
disease. Notwithstanding the small number of cases with
progressive disease, it appears that although the Topo2a level
predicts for response, it does not automatically predict for the
most resistant. Tumour resistance depends on complex interaction
of multiple factors. Similarly, the lack of significant correlation
between overall or progression-free survival withTopo2a may also
be attributed to the interplay of multiple factors.
Apart from Topo2a, the EGFR– status was predictive of pCR in
univariate and multivariate analysis in this study. In other studies,
EGFR-negative tumours had a better OS following neo-adjuvant
anthracyclines but did not predict for pCR (Buchholz et al, 2005
and Schippinger et al, 2007). The association of the EGFR  status
with pCR in this study may be explained by the downstream
signaling pathways activated by EGFR signaling resulting in
resistance to chemotherapy-induced apoptosis.
In our study, the ER negative status is an indicator of response
to anthracyclines on univariate analysis. In a larger series of
485 patients with LAPC (cT2-T4, N0-2, M0) ER/PR  tumours
were 12 times more likely to achieve a pCR to anthracyclines
(Po0.0001) (Colleoni et al, 2008). Thus the ER negative status may
be an indication of response to pre-operative chemotherapy in
LAPC.
The p53 is a known tumour suppressor and the nuclear protein
has an essential role in the regulation of cell cycle. Breast cancer
patients with p53 mutations or protein accumulation have been
shown to have worse survival (Miller et al, 2005). Pathological
complete response was associated with overexpressed p53 in our
series, as reported in other studies (Colleoni et al, 1999; Faneyte
et al, 2003; Mieog et al, 2006). Recent findings (Bertheau et al,
2007) indicate that non-inflammatory breast tumours containing
mutant TP53—in particular, basal-cell-like tumours—are very
sensitive to dose-dense epirubicin and cyclophosphamide che-
motherapy. The correlation between positive p53 and response has
been explained by the dose-dense regime used in the study. Other
authors (Faneyte et al, 2003) have tried to explain the association
of p53þstate with pCR with the following hypothesis: possibly, the
DNA damage that is initially tolerated by cells with mutated p53
(positive on IHC) decreases viability during subsequent tumour
proliferation. In contrast, with intact p53 (negative on IHC), DNA
repair mechanisms rescue cancer-cell viability. It must be
remembered that the correlation between p53 protein accumula-
tion and the presence of mutations is not absolute and hence, IHC
results must be interpreted with caution.
A recent progress into the molecular classification of breast
cancer includes the BP, originally identified from its gene-
expression profile. Our study used the stated definition of the BP
and found a high propensity of the cytokeratins in our LAPC
tumours. The high incidence probably reflects the highly selected
group of locally advanced breast cancers, which might have an
incidence of BP different from the whole breast cancer population.
It is sometimes perceived that BP tumours and triple-negative
tumours are synonymous and BP can be defined using a triple-
negative definition without the need for the expression of basal
markers. However, contrary to popular belief, it has been shown
that triple-negative tumours are a heterogeneous population that
may either be basal cytokeratin-positive or basal cytokeratin-
negative (Rakha et al, 2009). Hence, the basal cytokeratin-based
definition that has been widely used in the literature (Rakha et al,
2006, 2008) and in this study is probably more relevant in the
authors’ opinion.
As for response to anthracycline-based chemotherapy, the BP
status did not predict response/resistance to anthracyclines in our
series. The response of basal-like tumours to chemotherapy is not
well-defined (Rouzier et al, 2005; Rodrı ´guez-Pinilla et al, 2006;
Banerjee et al, 2006; Tan et al, 2008). In one study (Carey et al,
2007), the basal-like and HER2 subtypes, defined by hormone
receptor IHC only, had the highest rates of pCR to pre-operative
anthracycline-based chemotherapy, whereas the luminal tumours
responded poorly. Paradoxically, despite the significantly higher
prevalence of pCR in the basal-like group, patients with these
tumours still displayed the worst outcome. These discrepancies
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or patient populations studied, protein expression vs gene profiling,
as well as the molecular heterogeneity of basal breast tumours. As for
overall and progression-free survival, the BPþ-cohort tends to
fare worse. The BPþ group inherently defines cancers of a bad
prognostic group, documented well in the literature.
This study concludes that high Topo2a is the biomarker that has
the strongest correlation with pCR to neo-adjuvant anthracycline
combination. The strength of this study is the fact that these
patients had no previous cancer treatment, therefore the pCR rate
can be directly attributed to the FEC chemotherapy. Furthermore,
a battery of biomarkers were examined concurrently with Topo2a
and preselection based on HER2 status, was avoided. Given
the controversies surrounding the best and most accurate way to
assess the Topo2a-gene expression, the authors suggest that the
protein level, as determined by IHC, is an easily available as well as
summative end-point that should not be disregarded in future
studies. Further proteomic fine-tuning of quantitative analysis for
Topo2a protein levels may help clinicians tailor their selection of
chemotherapeutic agent for neo-adjuvant treatment. The alkylat-
ing agent administered with the anthracyclines may also be a
determinant of response and hence these associations should be
explored further. Other markers associated with pCR status are
also emerging for example, stromal gene signatures (Farmer et al,
2009) and the presence of tumour infiltrating lymphocytes
(Denkert et al, 2010). A combined genomic and proteomic analysis
on tissue and serum samples obtained sequentially during
neo-adjuvant chemotherapy may help define the molecular
response pathway, which can be utilised to select the optimal
treatment for the individual patient.
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